Препятствия для ухода за людьми с нечеткими визуальными данными о потерях из центра нейроинфламмации третьего уровня.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Delikaya Murat, Bereuter Charlotte, Schroeter Jan, Nowak Elisa, Dorsch Eva-Maria, Kilinska Lidia, Kuchling Joseph, Siebert Nadja, Behrens Janina, Paul Friedemann, Bellmann-Strobl Judith, Schmitz-Hübsch Tanja, Oertel Frederike Cosima
Аннотация
Оригинал публикации
Barriers to care for people with unclear visual loss-Data from a tertiary-level-of-care neuroinflammation center.
BACKGROUND: Visual symptoms are common in people with multiple sclerosis. The revised 2024 McDonald criteria include the optic nerve as a fifth anatomical region, underscoring the need for specific diagnostics. Although optical coherence tomography (OCT) and visual evoked potentials (VEP) are available, the extent of their routine pre-referral use is insufficiently documented. We evaluated pre-referral utilization and hypothesized that specific diagnostics are used less often than non-specific diagnostics and that differences are not explained by demographics alone.
METHODS: Retrospective cross-sectional study of 305 patients referred for visual symptoms to a tertiary neuroimmunology clinic in Germany. Analyses focused on people with multiple sclerosis (n = 112) and disease controls with neuromyelitis optica spectrum disorders or myelin oligodendrocyte glycoprotein-associated disease (pwNM; n = 36).
RESULTS: In people with multiple sclerosis, only 6.2% received OCT and 33% VEP for their visual complaints, compared to unspecific diagnostics such as cranial magnetic resonance imaging (58%) and lumbar puncture (42%) - independent of demographic factors.
CONCLUSION: The pre-referral use of specific neurovisual tests in people with multiple sclerosis with visual symptoms was low relative to non-specific procedures. This suggests heterogeneous integration of neurovisual testing across care levels. In light of the revised McDonald Criteria 2024, prospective multicenter studies should examine implementation and clinical impact.